Trade Heron Therapeutics, Inc. - HRTX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023374% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001151% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 2.12 |
| Open | 2.26 |
| 1-Year Change | -12.06% |
| Day's Range | 2.17 - 2.35 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 23, 2025 | 2.17 | -0.05 | -2.25% | 2.22 | 2.35 | 2.17 |
| Apr 22, 2025 | 2.12 | 0.17 | 8.72% | 1.95 | 2.17 | 1.95 |
| Apr 21, 2025 | 1.91 | 0.09 | 4.95% | 1.82 | 1.96 | 1.79 |
| Apr 17, 2025 | 1.81 | 0.01 | 0.56% | 1.80 | 1.84 | 1.77 |
| Apr 16, 2025 | 1.82 | -0.05 | -2.67% | 1.87 | 1.88 | 1.80 |
| Apr 15, 2025 | 1.90 | 0.00 | 0.00% | 1.90 | 1.97 | 1.90 |
| Apr 14, 2025 | 1.91 | -0.02 | -1.04% | 1.93 | 1.94 | 1.89 |
| Apr 11, 2025 | 1.88 | 0.12 | 6.82% | 1.76 | 1.88 | 1.76 |
| Apr 10, 2025 | 1.79 | 0.00 | 0.00% | 1.79 | 1.81 | 1.67 |
| Apr 9, 2025 | 1.85 | 0.19 | 11.45% | 1.66 | 1.90 | 1.63 |
| Apr 8, 2025 | 1.74 | -0.25 | -12.56% | 1.99 | 2.01 | 1.74 |
| Apr 7, 2025 | 1.93 | -0.01 | -0.52% | 1.94 | 1.98 | 1.82 |
| Apr 4, 2025 | 2.08 | 0.03 | 1.46% | 2.05 | 2.10 | 1.99 |
| Apr 3, 2025 | 2.12 | -0.06 | -2.75% | 2.18 | 2.20 | 2.10 |
| Apr 2, 2025 | 2.20 | 0.14 | 6.80% | 2.06 | 2.25 | 2.05 |
| Apr 1, 2025 | 2.09 | -0.08 | -3.69% | 2.17 | 2.17 | 2.08 |
| Mar 31, 2025 | 2.17 | -0.01 | -0.46% | 2.18 | 2.20 | 2.09 |
| Mar 28, 2025 | 2.23 | -0.07 | -3.04% | 2.30 | 2.30 | 2.20 |
| Mar 27, 2025 | 2.29 | 0.04 | 1.78% | 2.25 | 2.32 | 2.24 |
| Mar 26, 2025 | 2.27 | -0.04 | -1.73% | 2.31 | 2.35 | 2.25 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Heron Therapeutics, Inc. Company profile
About Heron Therapeutics Inc
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF (HTX-011), HTX-019, and HTX-034. HTX-011 is a dual-acting local anaesthetic that delivers a fixed-dose combination of the local anaesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. HTX-019 is an investigational agent for the prevention of postoperative nausea and vomiting. HTX-034 is a product candidate for postoperative pain management.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Heron Therapeutics Inc revenues decreased 3% to $86.3M. Net loss decreased 3% to $220.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects "Research and development - Balancing va decrease of 39% to $66.4M (expense), Stock-based Compensation in SGA decrease of 24% to $11.8M (expense).
Equity composition
Common Stock $.01 Par, 02/10, 50M auth., 40,143,227 issd. Insiders own 6.70%. IPO: 8/87, 2M shares @ $7.00 by Allen & Co. 2/92, private placement of 1,150,000 units (1 Share + 1 Warrant). 5/01, Name changed from Advanced Polymer Systems, Inc. FY'01 fncls. are restated. 05/07, 1-for-4 reverse stock split. 01/14, 1-for-20 Reverse stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
4242 Campus Point Court, Suite 200
SAN DIEGO
CALIFORNIA 92121
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com